Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Operating Expenses data on record, last reported at $22.2 million in Q1 2026.

  • On a quarterly basis, Operating Expenses rose 8.74% to $22.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $86.6 million, a 6.4% decrease, with the full-year FY2025 number at $84.8 million, down 16.81% from a year prior.
  • Operating Expenses reached $22.2 million in Q1 2026 per FULC's latest filing, down from $22.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for FULC hit a ceiling of $36.1 million in Q2 2022 and a floor of $19.4 million in Q4 2024.
  • A 5-year average of $26.0 million and a median of $27.5 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 50.09% in 2022, then crashed 32.69% in 2024.
  • Tracing FULC's Operating Expenses over 5 years: stood at $28.7 million in 2022, then increased by 0.72% to $28.9 million in 2023, then crashed by 32.69% to $19.4 million in 2024, then rose by 16.8% to $22.7 million in 2025, then fell by 2.23% to $22.2 million in 2026.
  • Business Quant data shows Operating Expenses for FULC at $22.2 million in Q1 2026, $22.7 million in Q4 2025, and $21.9 million in Q3 2025.